Get the Stockscreener App
1.49
0.67%
-0.01
After Hours:
1.49
Calidi Biotherapeutics Inc stock is traded at $1.49, with a volume of 92,624.
It is down -0.67% in the last 24 hours and down -5.70% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$1.50
Open:
$1.43
24h Volume:
92,624
Relative Volume:
0.34
Market Cap:
$8.02M
Revenue:
-
Net Income/Loss:
$-23.36M
P/E Ratio:
-2.0223
EPS:
-0.7368
Net Cash Flow:
-
1W Performance:
+2.76%
1M Performance:
-5.70%
6M Performance:
-69.72%
1Y Performance:
-94.72%
1-Day Range:
$1.40
$1.53
1-Week Range:
$1.40
$1.56
52-Week Range:
$1.10
$30.12
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.49 | 8.02M | 0 | -23.36M | 0 | -0.7368 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Certain Options of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-NOV-2025. - MarketScreener
What margin trends mean for Calidi Biotherapeutics Inc. stock2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com
Will Calidi Biotherapeutics Inc. stock outperform small cap peersMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
Will Calidi Biotherapeutics Inc. stock benefit from commodity pricesTrade Entry Summary & High Conviction Buy Zone Picks - newser.com
Will Calidi Biotherapeutics Inc. stock recover faster than industry2025 Year in Review & Reliable Entry Point Trade Alerts - newser.com
Why Calidi Biotherapeutics Inc. stock stays undervaluedQuarterly Portfolio Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Can Calidi Biotherapeutics Inc. stock beat market expectations this quarterWeekly Risk Summary & Proven Capital Preservation Tips - newser.com
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Commercial Appeal
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 - The Manila Times
Calidi Biotherapeutics (CLDI) Details RedTail, $560B Oncology Webinar Nov. 19 - Stock Titan
Is Calidi Biotherapeutics Inc. stock supported by strong cash flowsWeekly Profit Report & Free Real-Time Volume Trigger Notifications - newser.com
Will Calidi Biotherapeutics Inc. stock split increase liquidityJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - newser.com
Using data models to predict Calidi Biotherapeutics Inc. stock movementWeekly Profit Report & Proven Capital Preservation Methods - newser.com
Analyzing recovery setups for Calidi Biotherapeutics Inc. investorsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com
Will Calidi Biotherapeutics Inc. stock sustain bullish trend into 2025Earnings Overview Report & Community Consensus Stock Picks - newser.com
Signal strength of Calidi Biotherapeutics Inc. stock in tech scannersTrade Exit Report & Consistent Profit Trading Strategies - newser.com
Can Calidi Biotherapeutics Inc. stock rebound after recent weakness2025 Biggest Moves & AI Powered Buy and Sell Recommendations - newser.com
How analysts revise price targets for Calidi Biotherapeutics Inc. stockMarket Movers & Real-Time Chart Breakout Alerts - newser.com
What recovery options are there for Calidi Biotherapeutics Inc.Chart Signals & High Conviction Buy Zone Picks - newser.com
What momentum shifts mean for Calidi Biotherapeutics Inc.July 2025 PreEarnings & Consistent Profit Trading Strategies - newser.com
Calidi Biotherapeutics Inc.’s volatility index tracking explainedEarnings Recap Summary & High Return Stock Watch Alerts - newser.com
Full technical analysis of Calidi Biotherapeutics Inc. stockQuarterly Portfolio Review & Verified Momentum Watchlists - newser.com
Using RSI to spot recovery in Calidi Biotherapeutics Inc.July 2025 Outlook & Daily Momentum Trading Reports - newser.com
Can Calidi Biotherapeutics Inc. stock sustain institutional interestCEO Change & Safe Investment Capital Preservation Plans - Fundação Cultural do Pará
How Calidi Biotherapeutics Inc. stock reacts to stronger dollarWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights - The Manila Times
Calidi (NYSE American: CLDI) closes $6.9M offering; third-quarter net loss $5.2M - Stock Titan
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
0.19%
Cap:
|
Volume (24h):